PSW-1025

N/A

Report date: 2025/09/09 13:36:31

Base Information

Drug NamePSW-1025
Drug Alias NamePSW-1025
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOsaka UniversityJapan Agency For Medical Research And Development
China Registration ClassN/A

Develop Information

Active CompaniesOsaka UniversityJapan Agency For Medical Research And Development
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A